A phase 2, double-blind, randomized, safety and efficacy study of GE-145 versus Iodixanol in subjects undergoing cerebral angiography.

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222467

Enrollment

100

Registered

2014-04-22

Start date

2014-04-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The subjects undergoing cerebral angiography

Interventions

investigational material(s) Generic name etc : GE-145 INN of investigational material : Ioforminol (INN) Therapeutic category code : 721 X-ray contrast agents Dosage and Administration for Investigati

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The subjects who will undergo cerebral angiography with or without endovascular treatment.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Image quality Evaluation based on a criteria	—

Secondary

Measure	Time frame
Safety Adverse events after the administration of the study drug	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026